MEGNA , Matteo

BACKGROUND: Psoriatic arthritis (PsA) is an inflammatory condition which can affect up to 41% of psoriatic patients [1]. In 40-60% of pa-tients, PsA can determine cartilage destruction and joint deformities, hereby heavily impacting physical function and quality of life, even increas-ing the risk of death compared to the general population [1]....

Purpose: Psoriasis, a common systemic inflammatory disorder, presents with gender-related differences in the quality of life (QoL) and treatment outcomes. This post hoc analysis from the Phase 3b SUPREME study explored gender-related differences in patient characteristics and efficacy of secukinumab 300 mg on Psoriasis Area and Severity Index...

BackgroundGuselkumab is a humanized monoclonal antibody that binds selectively to the p19 subunit of interleukin-23, which has shown efficacy in patients with previous incomplete response to ustekinumab in the NAVIGATE clinical trial. ObjectivesWe conducted a 104-week multicenter retrospective study to assess the effectiveness and safety of...